In 2020, antibodies driven by their widespread application in research, diagnosis, drug development and disease treatment, accounted for the largest share of the in-vitro diagnostic (IVD) market.

The traditional method of hybridoma technology is popularly used to produce highly specific, naturally-matured in vivo mAbs. However, in several cases, the mAb yields are not as high as expected. There are a few ways by which a poorly performing cell line can be rescued.

InVivo offers three unique solutions that can be adapted to meet customers’ specific yield requirements, product validation needs and timelines.

These include:
• Recloning of hybridoma cell line and selection for high-producer clones
• Transition from mAb to recombinant antibody (recAb) production via transient gene expression (TGE) in human embryonic kidney (HEK) cells
• Transition from mAb to recombinant antibody (recAb) production via stable gene expression (SGE) in Chinese hamster ovary (CHO) cells

This case study outlines three examples of how InVivo identified the most suitable method of antibody production to fit customer needs and project requirements.